941 / 1266
A Phase 1 Study of AZD6244 in Children with Recurrent
or Refractory Low Grade Gliomas: A Pediatric Brain
Tumor Consortium Report
.
Anuradha Banerjee, Regina Jakacki, Arzu Onar-Thomas, Shengjie Wu, Theodore Nicolaides, David C. Turner, Stacye Richardson, Tina Young-Poussaint, Joanna
Phillips, Michael Prados, Roger Packer, Ibrahim Qaddoumi, Sridharan Gururangan, Stewart Goldman, Ian Pollack, Austin Doyle, Clinton F. Stewart, James
Boyett, Larry Kun, Maryam Fouladi
Age > 3 and < 21 years with recurrent or refractory low grade glioma
that has failed prior chemo or radiotherapy
Drug administered by mouth, daily, BID continuously
One course=28 days, up to 26 courses of treatment allowed
Dose limiting toxicity (DLT) observation period is end of 1
st
28 day cycle
3 dosage levels (DL) investigated
DL0, 25 mg/m2/dose, BID
DL1, 33 mg/m2/dose, BID
DL2, 43 mg/m2/dose, BID